Home Cart Sign in  
Chemical Structure| 100644-67-5 Chemical Structure| 100644-67-5

Structure of 100644-67-5

Chemical Structure| 100644-67-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 100644-67-5 ]

CAS No. :100644-67-5
Formula : C6H7N5O
M.W : 165.15
SMILES Code : COC1=NC(N)=NC2=C1C=NN2
MDL No. :MFCD09264064
InChI Key :JGSDDGDWMGPLPH-UHFFFAOYSA-N
Pubchem ID :11252197

Safety of [ 100644-67-5 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 100644-67-5 ] Show Less

Physicochemical Properties

Num. heavy atoms 12
Num. arom. heavy atoms 9
Fraction Csp3 0.17
Num. rotatable bonds 1
Num. H-bond acceptors 4.0
Num. H-bond donors 2.0
Molar Refractivity 42.58
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

89.71 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.62
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.12
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.05
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.18
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.34
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.17

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.43
Solubility 6.16 mg/ml ; 0.0373 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.56
Solubility 4.55 mg/ml ; 0.0276 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.93
Solubility 1.96 mg/ml ; 0.0119 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.22 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.09

Application In Synthesis of [ 100644-67-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 100644-67-5 ]

[ 100644-67-5 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 3056-12-0 ]
  • [ 100644-67-5 ]
  • [ 109737-90-8 ]
  • [ 100644-68-6 ]
  • 2
  • [ 3056-12-0 ]
  • [ 100644-67-5 ]
  • [ 109737-90-8 ]
  • [ 100644-68-6 ]
  • 6-amino-1-(2'-deoxy-3',5'-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl)-4-methoxy-1H-pyrazolo<3,4-d>pyrimidine [ No CAS ]
  • 3
  • [ 3056-12-0 ]
  • [ 100644-67-5 ]
  • [ 100644-69-7 ]
  • 4
  • [ 124-41-4 ]
  • [ 100644-65-3 ]
  • [ 100644-67-5 ]
YieldReaction ConditionsOperation in experiment
95.4% In methanol; at 65℃; for 2h;Inert atmosphere; A solution of the compound of formula (VH) (800 mg, 4.73 mmol) was added to 12.5 mL of anhydrous methanol and nitrogen purged. The solution was transferred to a 2.3 M solution of 5.4 M sodium methoxide in methanol. After refluxing at 65 C for 2 h, 7.5 mL of acetic acid was added 5min, the solvent was removed and dried in vacuo to give 745 mg of a tan solid 95.4%.
  • 5
  • [ 4330-21-6 ]
  • [ 100644-67-5 ]
  • [ 100644-68-6 ]
  • 6
  • [ 174538-17-1 ]
  • [ 100644-67-5 ]
  • diethyl <7-(6-amino-4,5-dihydro-4-methoxy-1H-pyrazolo<3,4-d>pyrimidin-1-yl)-1,1-difluoroheptyl>phosphonate [ No CAS ]
  • 7
  • [ 100644-67-5 ]
  • [ 174537-96-3 ]
  • [ 174538-23-9 ]
  • 8
  • [ 100644-67-5 ]
  • [ 174537-97-4 ]
  • [ 174538-24-0 ]
  • 9
  • [ 100644-67-5 ]
  • [ 203179-99-1 ]
  • 10
  • [ 100644-67-5 ]
  • [ 203180-01-2 ]
YieldReaction ConditionsOperation in experiment
78.8% With sodium acetate; Iodine monochloride; In water; at 95℃; for 2.5h;Darkness; Inert atmosphere; Sodium acetate and the formula (V) compound (675mg, 4.09mmol) (1.73g, 21.08mmol) was added 15mL of water, under dark, adding iodine chloride (905mg, 5.58mmol), nitrogen, 95 C under reflux for 2.5h After adding 20mL of water and sodium metabisulfite (1.1g, 5.79mmol), stirred at room temperature for 0.5h filtered in vacuo Dried to give a pale red solid 938mg, yield 78.8%.
  • 11
  • [ 100644-67-5 ]
  • [ 109737-90-8 ]
  • 12
  • [ 100644-67-5 ]
  • (2R,3S,5R)-5-(6-Amino-3-iodo-4-methoxy-pyrazolo[3,4-d]pyrimidin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol [ No CAS ]
  • 13
  • [ 100644-67-5 ]
  • (2R,3S,5R)-5-(6-Amino-3-bromo-4-methoxy-pyrazolo[3,4-d]pyrimidin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol [ No CAS ]
  • 14
  • [ 100644-67-5 ]
  • [ 203180-03-4 ]
  • 15
  • [ 100644-67-5 ]
  • [ 203180-05-6 ]
  • 16
  • [ 100644-67-5 ]
  • [7-(6-Amino-4-oxo-4,5-dihydro-pyrazolo[3,4-d]pyrimidin-1-yl)-1,1-difluoro-heptyl]-phosphonic acid [ No CAS ]
  • 22
  • [ 100644-67-5 ]
  • 6-Amino-1-(2'-deoxy-α-D-erythro-pentofuranosyl)-4-methoxy-1H-pyrazolo<3,4-d>pyrimidine [ No CAS ]
  • 23
  • [ 100644-67-5 ]
  • 6-amino-1-<2',3'-dideoxy-β-D-glycero-pentofuranosyl>-1H-pyrazolo<3,4-d>pyrimidin-4(5H)-one [ No CAS ]
  • 24
  • [ 100644-67-5 ]
  • [ 117818-23-2 ]
  • 25
  • [ 100644-67-5 ]
  • [ 117818-22-1 ]
  • 26
  • [ 100644-67-5 ]
  • [ 117818-24-3 ]
  • 27
  • [ 100644-67-5 ]
  • [ 117818-26-5 ]
  • 28
  • [ 100644-67-5 ]
  • [ 117852-20-7 ]
  • 29
  • [ 100644-67-5 ]
  • 6-amino-1-<2'-deoxy-3',5'-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl>-1H-pyrazolo<3,4-d>pyrimidin-4(5H)-one [ No CAS ]
  • 30
  • [ 452-51-7 ]
  • [ 100644-67-5 ]
  • [ 100644-69-7 ]
  • 31
  • [ 961-07-9 ]
  • [ 100644-67-5 ]
  • [ 100644-69-7 ]
  • 32
  • [ 100644-67-5 ]
  • C25H20Cl2IN5O6 [ No CAS ]
  • 33
  • [ 100644-67-5 ]
  • [ 183274-53-5 ]
  • 34
  • [ 100644-67-5 ]
  • C32H23Cl3IN5O8 [ No CAS ]
  • 35
  • [ 100644-67-5 ]
  • C15H15F3N6O5 [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 100644-67-5 ]

Ethers

Chemical Structure| 696-45-7

A108326 [696-45-7]

4-Amino-6-methoxypyrimidine

Similarity: 0.61

Chemical Structure| 3289-50-7

A130482 [3289-50-7]

4-Amino-2,6-dimethoxypyrimidine

Similarity: 0.59

Chemical Structure| 5734-64-5

A173062 [5734-64-5]

4-Chloro-6-methoxypyrimidin-2-amine

Similarity: 0.59

Chemical Structure| 119368-03-5

A381274 [119368-03-5]

4-Methoxy-1H-pyrazolo[3,4-b]pyridine

Similarity: 0.58

Chemical Structure| 72411-89-3

A147432 [72411-89-3]

4-Methoxypyrimidine-5-carboxylic acid

Similarity: 0.56

Amines

Chemical Structure| 29939-37-5

A193465 [29939-37-5]

4-Hydroxy-6-hydrazinylpyrimidine

Similarity: 0.65

Chemical Structure| 15400-53-0

A107500 [15400-53-0]

Ethyl 2-amino-4-hydroxypyrimidine-5-carboxylate

Similarity: 0.63

Chemical Structure| 696-45-7

A108326 [696-45-7]

4-Amino-6-methoxypyrimidine

Similarity: 0.61

Chemical Structure| 3289-50-7

A130482 [3289-50-7]

4-Amino-2,6-dimethoxypyrimidine

Similarity: 0.59

Chemical Structure| 5734-64-5

A173062 [5734-64-5]

4-Chloro-6-methoxypyrimidin-2-amine

Similarity: 0.59

Related Parent Nucleus of
[ 100644-67-5 ]

Other Aromatic Heterocycles

Chemical Structure| 2465-59-0

A115853 [2465-59-0]

1H-Pyrazolo[3,4-d]pyrimidine-4,6-diol

Similarity: 0.84

Chemical Structure| 271-80-7

A312546 [271-80-7]

1H-Pyrazolo[3,4-d]pyrimidine

Similarity: 0.69

Chemical Structure| 119368-03-5

A381274 [119368-03-5]

4-Methoxy-1H-pyrazolo[3,4-b]pyridine

Similarity: 0.58

Chemical Structure| 115932-00-8

A150816 [115932-00-8]

Ethyl pyrazolo[1,5-a]pyrimidine-3-carboxylate

Similarity: 0.57

Chemical Structure| 29274-22-4

A103418 [29274-22-4]

Pyrazolo[1,5-a]pyrimidin-5-ol

Similarity: 0.56